Evolution and intelligent design in drug development

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Protein kinase networks are crucial for cellular complexity but implicated in diseases like cancer.
• Kinase inhibitors are key cancer drug targets, yet achieving specificity remains a challenge.
• Understanding the molecular basis of existing drugs like Gleevec offers new design insights.

Purpose of the Study:

• To explore novel strategies for designing specific kinase inhibitors.
• To leverage recent breakthroughs in understanding drug mechanisms.
• To identify new approaches for combating evolving cancer drug resistance.

Main Methods:

• Utilizing an "old" biochemical technique: stopped-flow kinetics.
• Studying ancient enzyme "ancestors" dating back a billion years.
• Analyzing the molecular basis of clinical success for cancer drugs like Gleevec.

Main Results:

• A recent breakthrough has illuminated the molecular underpinnings of Gleevec's efficacy.
• The combination of historical methods and ancient enzymes provides a novel perspective.
• This interdisciplinary approach offers unexpected insights for future drug design.

Conclusions:

• Ancient enzymes and established kinetic methods can inform modern drug discovery.
• New strategies are needed to overcome the challenges in designing specific kinase inhibitors.
• This perspective highlights a promising, albeit unexpected, direction for intelligent cancer drug design.